Innate Pharma S.A. (EPA:IPH)

Innate Pharma Statistics

Total Valuation

Innate Pharma has a market cap or net worth of EUR 179.54 million. The enterprise value is 146.54 million.

Market Cap	179.54M
Enterprise Value	146.54M

Important Dates

The next estimated earnings date is Friday, December 19, 2025.

Earnings Date	Dec 19, 2025
Ex-Dividend Date	n/a

Share Statistics

Innate Pharma has 92.17 million shares outstanding. The number of shares has increased by 4.15% in one year.

Current Share Class	92.17M
Shares Outstanding	92.17M
Shares Change (YoY)	+4.15%
Shares Change (QoQ)	+7.02%
Owned by Insiders (%)	0.98%
Owned by Institutions (%)	1.90%
Float	59.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	8.38
PS Ratio	14.21
PB Ratio	34.90
P/TBV Ratio	34.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.18
EV / Sales	11.60
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.55

Financial Position

The company has a current ratio of 2.21, with a Debt / Equity ratio of 5.25.

Current Ratio	2.21
Quick Ratio	2.08
Debt / Equity	5.25
Debt / EBITDA	n/a
Debt / FCF	-0.66
Interest Coverage	-102.40

Financial Efficiency

Return on equity (ROE) is -271.37% and return on invested capital (ROIC) is -65.68%.

Return on Equity (ROE)	-271.37%
Return on Assets (ROA)	-25.92%
Return on Invested Capital (ROIC)	-65.68%
Return on Capital Employed (ROCE)	-79.81%
Revenue Per Employee	72,621
Profits Per Employee	-264,661
Employee Count	181
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.85% in the last 52 weeks. The beta is 0.80, so Innate Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	-3.85%
50-Day Moving Average	1.80
200-Day Moving Average	1.82
Relative Strength Index (RSI)	56.85
Average Volume (20 Days)	268,623

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Innate Pharma had revenue of EUR 12.64 million and -46.05 million in losses. Loss per share was -0.55.

Revenue	12.64M
Gross Profit	-30.79M
Operating Income	-50.69M
Pretax Income	-46.05M
Net Income	-46.05M
EBITDA	-49.77M
EBIT	-50.69M
Loss Per Share	-0.55

Balance Sheet

The company has 60.03 million in cash and 27.03 million in debt, giving a net cash position of 33.00 million or 0.36 per share.

Cash & Cash Equivalents	60.03M
Total Debt	27.03M
Net Cash	33.00M
Net Cash Per Share	0.36
Equity (Book Value)	5.14M
Book Value Per Share	0.06
Working Capital	35.55M

Cash Flow

In the last 12 months, operating cash flow was -41.10 million and capital expenditures -166,000, giving a free cash flow of -41.26 million.

Operating Cash Flow	-41.10M
Capital Expenditures	-166,000
Free Cash Flow	-41.26M
FCF Per Share	-0.45

Margins

Gross Margin	-243.65%
Operating Margin	-401.15%
Pretax Margin	-364.44%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Innate Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.15%
Shareholder Yield	-4.15%
Earnings Yield	-25.65%
FCF Yield	-22.98%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innate Pharma has an Altman Z-Score of -6.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.27
Piotroski F-Score	2